Kamilli I, Gresser U, Pellkofer T, Löffler W, Zöllner N
Medizinische Poliklinik, Universität München.
Z Rheumatol. 1989 Nov-Dec;48(6):307-12.
A single oral dose of 50 mg irtemazole exhibited a clear cut uricosuric effect in five patients with hyperuricemia and normal renal function. The average maximal decrease of plasma uric acid was 46.1% compared to the initial value; it was reached between 6 h and 12 h after drug administration. Extent and course of plasma uric acid showed no differences between normouricemic (5) and hyperuricemic subjects. In four patients suffering from hyperuricemia and renal insufficiency only a minor effect of irtemazole was seen. The average maximal decrease of plasma uric acid reached 12.8% compared to the initial value. It occurred between 8 h and 12 h after drug ingestion. In both normouricemic and hyperuricemic subjects irtemazole acts more quickly than benzbromarone and probenecid. The duration of its uricosuric effect is shorter. Like benzbromarone, irtemazole exhibits only a minor effect in patients with reduced creatinine clearance.
单次口服50毫克依特马唑对5名高尿酸血症且肾功能正常的患者显示出明显的促尿酸排泄作用。与初始值相比,血浆尿酸平均最大降幅为46.1%;在给药后6至12小时达到该降幅。正常尿酸血症患者(5名)和高尿酸血症患者的血浆尿酸水平及变化过程无差异。在4名患有高尿酸血症和肾功能不全的患者中,仅观察到依特马唑有轻微作用。与初始值相比,血浆尿酸平均最大降幅达12.8%。在服药后8至12小时出现该降幅。在正常尿酸血症和高尿酸血症患者中,依特马唑的起效比苯溴马隆和丙磺舒更快。其促尿酸排泄作用的持续时间较短。与苯溴马隆一样,依特马唑对肌酐清除率降低的患者仅显示出轻微作用。